Marjorie Shaw Phillips1. 1. Department of Pharmacy, Georgia Health Sciences Health System, 1120 15th Street, BI-2101, Augusta, GA 30912, USA. mphillip@georgiahealth.edu
Abstract
PURPOSE: The results of a 2008 survey by the U.S. Pharmacopeia (USP) Safe Medication Use Expert Committee assessing the use of standardized i.v. drug concentrations at U.S. health care institutions are presented. METHODS: To evaluate progress toward the goal of standardizing and limiting the number of i.v. infusion concentrations of high-risk medications, particularly those commonly used in pediatric patients, a USP-appointed expert committee surveyed a nationally representative sample of hospital and health-system pharmacy directors; 229 usable survey responses and 174 requested lists of routinely used or "standard" concentrations (i.e., those designed to meet the needs of at least 90% of the target adult, pediatric, and neonatal populations) were received. RESULTS: The survey responses indicated that multiple concentrations of high-risk drugs are still commonly used; in some instances, as many as four standard concentrations of a single medication were reported to be in use for a particular age group. Depending on the drug and target group, the proportion of respondents reporting the use of one standard concentration for a given drug ranged from 15% to 79%. The survey data informed and helped focus the USP expert committee's efforts to develop recommended standard concentrations for 10 high-alert drugs. Also presented in this article are general principles drafted by the USP committee to guide the development of local and national standard concentrations. CONCLUSION: The results of a national USP survey indicate that many institutions do not use standard i.v. infusion concentrations of commonly used high-risk medications in adult, pediatric, or neonatal patient populations.
PURPOSE: The results of a 2008 survey by the U.S. Pharmacopeia (USP) Safe Medication Use Expert Committee assessing the use of standardized i.v. drug concentrations at U.S. health care institutions are presented. METHODS: To evaluate progress toward the goal of standardizing and limiting the number of i.v. infusion concentrations of high-risk medications, particularly those commonly used in pediatric patients, a USP-appointed expert committee surveyed a nationally representative sample of hospital and health-system pharmacy directors; 229 usable survey responses and 174 requested lists of routinely used or "standard" concentrations (i.e., those designed to meet the needs of at least 90% of the target adult, pediatric, and neonatal populations) were received. RESULTS: The survey responses indicated that multiple concentrations of high-risk drugs are still commonly used; in some instances, as many as four standard concentrations of a single medication were reported to be in use for a particular age group. Depending on the drug and target group, the proportion of respondents reporting the use of one standard concentration for a given drug ranged from 15% to 79%. The survey data informed and helped focus the USP expert committee's efforts to develop recommended standard concentrations for 10 high-alert drugs. Also presented in this article are general principles drafted by the USP committee to guide the development of local and national standard concentrations. CONCLUSION: The results of a national USP survey indicate that many institutions do not use standard i.v. infusion concentrations of commonly used high-risk medications in adult, pediatric, or neonatal patient populations.
Authors: Debra L Child; Zhun Cao; Laura E Seiberlich; Harold Brown; Jordan Greenberg; Anne Swanson; Martha R Sewall; Scott B Robinson Journal: Clinicoecon Outcomes Res Date: 2014-12-15
Authors: Silvia Manrique-Rodríguez; Irene Heras-Hidalgo; M Sagrario Pernia-López; Ana Herranz-Alonso; M Camino Del Río Pisabarro; M Belén Suárez-Mier; M Antonia Cubero-Pérez; Verónica Viera-Rodríguez; Noemí Cortés-Rey; Elizabeth Lafuente-Cabrero; M Carmen Martínez-Ortega; Esther Bermejo-López; Cristina Díez-Sáenz; Piedad López-Sánchez; M Luisa Gaspar-Carreño; Rubén Achau-Muñoz; Juan F Márquez-Peiró; Marta Valera-Rubio; Esther Domingo-Chiva; Irene Aquerreta-González; Ignacio Pellín Ariño; M Cruz Martín-Delgado; Manuel Herrera-Gutiérrez; Federico Gordo-Vidal; Pedro Rascado-Sedes; Emilio García-Prieto; Lucas J Fernández-Sánchez; Sara Fox-Carpentieri; Carlos Lamela-Piteira; Luis Guerra-Sánchez; Miguel Jiménez-Aguado; María Sanjurjo-Sáez Journal: Drugs R D Date: 2020-12-21